(Q45340990)

13 December 2017

title

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia (English)

1 reference

13 December 2017

1 reference

4

1 reference

13 December 2017

11

Didier Blaise

1 reference

13 December 2017

Raynier Devillier

1

1 reference

13 December 2017

Roberto Crocchiolo

2

1 reference

13 December 2017

Anne Etienne

3

1 reference

13 December 2017

Aude Charbonnier

5

1 reference

13 December 2017

Sabine Fürst

6

1 reference

13 December 2017

Jean El-Cheikh

7

1 reference

13 December 2017

Evelyne D'Incan

8

1 reference

13 December 2017

Jérôme Rey

9

1 reference

13 December 2017

Catherine Faucher

10

1 reference

13 December 2017

Norbert Vey

12

1 reference

13 December 2017

publication date

19 November 2012

1 reference

13 December 2017

1 reference

13 December 2017

volume

54

1 reference

13 December 2017

issue

6

1 reference

13 December 2017

page(s)

1228-1234

1 reference

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.741230

10.3109/10428194.2012.741230

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference